Story thread · 3 reports / 3 sources
Moonwalk reloads with $70M and new RNAi prospects for obesity
biopharmadive.com · 6d
The California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.
First report: Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease — genengnews.com, 6d
The coverage
- Moonwalk raises $70M to test siRNA treatment for obesity
endpts.com · 6d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.